Neurology: Volume 99, Number 22, November 29, 2022 Exam #2 - Long-term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder and MOG Antibody Disease
About this course
- Released: 11/29/2022
- Expires: 11/29/2025
LONG-TERM EFFECTIVENESS AND SAFETY OF RITUXIMAB IN NEUROMYELITIS OPTICA SPECTRUM DISORDER AND MOG ANTIBODY DISEASE
Upon completion of the article by Barreras et al, the participant should be able to:
- State the most common reason for rituximab discontinuation found in this study
- Discuss the impact of rituximab on relapse rate before and after treatment for neuromyelitis optica spectrum disorder (NMSOD) and MOG antibody disease (MOGAD) in this study
- State the most common infection seen in patients during treatment for MOGAD and NMSOD in this study
CORE COMPETENCIES:The article by Barreras et al covers the following core competency:
- Medical Knowledge
AUTHOR DISCLOSURES:Refer to listing above the references in each article.
THIS PAGE IS REQUIRED READING BEFORE BEGINNING ALL ACCME-ACCREDITED COURSES
The American Academy of Neurology Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
MISSION STATEMENT/PROGRAM OBJECTIVES
After evaluating a specific article published in Neurology, participants in the CME activity should be able to demonstrate an increase in, or affirmation of, their knowledge of clinical medicine. Participants should be able to evaluate the appropriateness of the clinical information as it applies to the provision of patient care.
This program is designed for physicians who are involved in providing patient care and who wish to advance their current knowledge of clinical medicine.
AMA CREDIT DESIGNATION STATEMENT
The American Academy of Neurology Institute designates this journal-based-CME activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME Journal Editors: James W.M. Owens, Jr., MD, PhD: Scientific Advisory Boards: Member of data safety monitoring board, RaSURE study, AADi Bioscience, Inc. Funding for travel or speaker honoraria: Honoraria, Program Director, AAN Annual Meeting. Editorial Boards: CME Editor, Neurology and Adam Kelly, MD: Editorial Boards: Neurology, CME editor, ongoing since January 2016. Other activities: Question writing for American Academy of Neurology activities, including Continuum. AAN staff members editing the test (K. Aman Ramm, H. McNiff) have no disclosures. All relevant financial relationships have been mitigated.
This CME program receives no commercial support.